Plasma Cell Myeloma
Conditions
Keywords
Plasma Cell Myeloma, MRD-Negative, MRD-Negative Remission, Memorial Sloan Kettering Cancer Center, 19-422
Brief summary
This study will test whether stopping maintenance therapy in people with multiple myeloma in MRD-negative remission has the same effect on disease control as continuing this therapy. The study will look at whether people currently on maintenance therapy can safely stop this treatment and continue with active surveillance instead while keeping their MRD-negative remission status for at least 1 year.
Interventions
OTHERCessation of continuous matinenace therapy
Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with plasma cell myeloma treated with any number of prior lines of therapy, who at the time of study enrollment have had sustained MRD-negativity at a given timepoint and a subsequent time point with an interval of 3 or more years while on continuous maintenance therapy. MRD-negativity is defined per the International Myeloma Working Group Consensus Panel. * MRD positivity will be defined by detection of 1 or more neoplastic plasma cells in 10\^5 nucleated cells by flow cytometry as per IMWG criteria (i.e., sensitivity of 10-5) * Age \>/= 18 years with ECOG performance status \</= 2 * Patients must be able to understand and be willing to sign a voluntary informed consent form and agree to compliance with the protocol schedule; with the knowledge that they may withdraw consent at any time without impact on future medical care
Exclusion criteria
* Patients found to be MRD-positive at time of screening * Patients with plasma cell leukemia or other disorder of plasma cell neoplasm * Patient who are receiving other therapy with the intent of treating myeloma with the exception of bisphosphonates * Patients being treated for another, potentially life-limiting malignancy with 3-year lead-in to study enrollment, with the exception of non-melanoma skin cancer or in situ malignancy or malignancies that have received definitive curative therapy * Prior organ transplant or condition requiring immunosuppressive therapy * Prior allogeneic hematopoietic cell transplant * Patients with any other ongoing, concomitant, comorbid illness including but not limited to uncontrolled diabetes, NYHA class III or IV heart failure, uncontrolled coronary artery disease/arrhythmia, psychiatric or social disorder that would compromise compliance with the study schema
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 1 year | Maintaining a MRD-negative state for one year of enrolling on this study |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORNeha Korde, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed